|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 6-K filed Oct 27, 2005. Net Gain on Divestment of Businesses
The net gain on divestment of businesses in the third quarter of 2005 was $23.3 million, compared to a net gain of $5.6 million in the same period of 2004. Included in the net gain in the third quarter of 2005 is $23.0 million of contingent consideration related to the divestment of Zonegran (zonisamide) to Eisai Co. Ltd (Eisai). In addition, Elan expects to receive additional consideration of $25.0 million from Eisai if generic zonisamide is not introduced into the U.S. market before January 1, 2006.
This excerpt taken from the ELN 6-K filed Jul 28, 2005. Net Gain on Divestment of Businesses
The net gain on divestment of businesses in the second quarter of 2005 was $21.0 million, compared to a net gain of $38.9 million in the same period of 2004. Included in the net gain in the second quarter of 2005 is $20.0 million (2004: $38.7 million) of contingent consideration related to the divestment of Zonegran (zonisamide). In addition, Elan expects to receive additional consideration of $48.0 million from Eisai if generic zonisamide is not introduced into the U.S. market before January 1, 2006.
11
Elan Second Quarter 2005 Financial Results
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||